Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Brensocatib · Brinsupri, INS-1007

Small molecule · Inhibitor of dipeptidyl peptidase 1 (CTSC) · developed by Insmed

Approved FDA, Aug 2025
INSM Developer
5 Registered trials

What is Brensocatib?

Brensocatib is an orally bioavailable, small molecule that competitively and reversibly inhibits dipeptidyl peptidase 1 (DPP1), reducing activation of neutrophil serine proteases such as neutrophil elastase during neutrophil maturation. It is studied in non-cystic fibrosis bronchiectasis and COVID-19.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Brinsupri, INS-1007, AZD-7986
Drug type
Small molecule
Targets
dipeptidyl peptidase 1 (CTSC), neutrophil elastase (ELANE) (secondary target), cathepsin G (CTSG) (secondary target), proteinase 3 (PRTN3) (secondary target)
Mechanism
Inhibitor of dipeptidyl peptidase 1 (CTSC)
Pathways
neutrophil serine protease activation during neutrophil maturation
Therapy area
Infectious disease, Respiratory
Developer
Insmed Inc (INSM)
FDA status
Approved as Brinsupri (August 12, 2025), NDA217673 · FDA label
UNII
25CG88L0BB

✅ FDA-approved uses

From the indications section of the FDA label (version of Mar 16, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04594369 Phase 3 Non-Cystic Fibrosis Bronchiectasis Completed INSM
NCT04817332 Phase 3 Covid19 Completed INSM
NCT06344728 Phase 1 Healthy Participants Completed INSM
NCT05652257 Phase 1 Healthy Volunteers Completed INSM
NCT05927597 Phase 1 Healthy Volunteers Completed INSM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Covid19Healthy ParticipantsHealthy VolunteersNon-Cystic Fibrosis Bronchiectasis

More from Insmed

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the INSM page.

Follow INSM, the company behind Brensocatib

See INSM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

INSM catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.